Clarivate

Clarivate Closes $488.4M LS&H Sale as Organic Growth Hits 0.4%

Image
Clarivate Closes $488.4M LS&H Sale as Organic Growth Hits 0.4%

LONDON – November 03, 2026 -- Clarivate Plc (NYSE: CLVT) closed the sale of its Life Sciences & Healthcare (LS&H) segment on October 6, 2026 for net cash proceeds of $488.4 million, and reported third-quarter organic revenue growth of 0.4% for continuing operations alongside a $80.8 million net loss driven by a goodwill impairment.

Organic ACV rises 1.8% as subscriptions replace transactional sales

Organic annual contract value (ACV) for continuing operations grew 1.8% against September 30, 2025. Organic subscription revenue increased 1.5%, helped by new sales and pricing actions, while organic re-occurring revenue rose 0.7% on higher IP volumes. Organic recurring revenue, the combination of both, grew 1.3%, or $5.7 million.

Clarivate Names 22 Citation Laureates, Honoring GLP-1 Drug Pioneers

Image
Clarivate Names 22 Citation Laureates, Honoring GLP-1 Drug Pioneers

London – September 20, 2026 -- Clarivate Plc (NYSE: CLVT) named 22 researchers as its Citation Laureates 2026, identifying scientists whose work the company's Institute for Scientific Information (ISI) considers Nobel-class ahead of this year's Nobel Prize announcements. Since the program began in 2002, 89 previously named Citation Laureates have gone on to win Nobel Prizes.

Study Challenges Fear-Based Sales Pitch, Finds 31% Recall Gain

Image
Study Challenges Fear-Based Sales Pitch, Finds 31% Recall Gain

Waltham, Mass. – September 18, 2026 -- Sales messages that tell B2B technology buyers they control a positive outcome hold attention 31% longer and produce 31% better recall than fear-based pitches, according to new neuroscience research from Allego, Inc. that challenges a nearly 50-year-old sales doctrine.

The study, conducted with cognitive neuroscientist Dr. Carmen Simon of Enhancive, tests the real-world application of Prospect Theory, the 1979 model by Daniel Kahneman and Amos Tversky holding that fear of loss motivates buyers more than potential gain. Kahneman won the 2002 Nobel Memorial Prize in Economics partly for that work.